Company Overview
Snapshot
Founded in October 2021 by Yogev Debbi and Roy Nevo, Mana.bio operates with 11–50 employees. The company has raised $24.5 million across two funding rounds from five investors. In October 2023, Mana.bio secured seed funding from Andreessen Horowitz and Base4 Capital.
Business overview
Mana.bio specializes in AI-based drug-delivery solutions, focusing on gene therapy. The company's technology integrates machine learning and nanotechnology to develop drug-delivery systems, particularly a platform for lipid nanoparticle development for oligonucleotide therapies, including mRNA-based therapeutics, vaccines, and gene therapy. Mana.bio operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery, targeting the Life Sciences and Biotechnology markets.
Strategic signal
In September 2025, Mana.bio launched Mina™, the first large language model specifically designed for lipid nanoparticles (LNPs). This AI-powered tool, publicly available for free, aims to accelerate scientific discovery in RNA delivery and therapeutics development by providing predictive modeling, curated data retrieval, and formulation optimization. This signals Mana.bio's commitment to leveraging AI to bridge the gap between laboratory research and clinical application, enhancing innovation in gene therapy and RNA-based medicines.
Log in to access full profile ›Company Intelligence Q&A
- What is Mana.bio's core focus?
- Mana.bio focuses on AI-based programmable drug delivery, specifically developing solutions for gene therapy through the integration of machine learning and nanotechnology.
- When was Mana.bio founded and by whom?
- Mana.bio was founded in October 2021 by Co-founder & CEO Yogev Debbi and Co-founder & CTO Roy Nevo.
- What significant product did Mana.bio launch in September 2025?
- In September 2025, Mana.bio launched Mina™, the world's first large language model-powered AI agent for lipid nanoparticles, designed to accelerate scientific discovery in RNA delivery and therapeutics.
- Which investors participated in Mana.bio's October 2023 funding round?
- In October 2023, Mana.bio secured seed funding from Andreessen Horowitz and Base4 Capital.
- How is Mana.bio leveraging AI in its drug delivery platform?
- In December 2024, Mana.bio presented data on broad improvements to systemic lipid nanoparticle tolerability by leveraging a novel AI-driven safety model, demonstrating a 100-fold increase in in-vivo potency for their second-generation LNP candidate after three months of iterative development.